Previous close | 732.20 |
Open | 725.00 |
Bid | 723.34 x 1000 |
Ask | 723.81 x 1100 |
Day's range | 718.30 - 727.99 |
52-week range | 380.77 - 800.78 |
Volume | |
Avg. volume | 3,063,427 |
Market cap | 689.182B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 125.41 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 5.20 (0.71%) |
Ex-dividend date | 14 Feb 2024 |
1y target est | N/A |
Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.